接受一线化疗联合或不联合抗EGFR单克隆抗体治疗的晚期胃癌患者中严重维生素D缺乏高发(EXPAND试验)且无预后影响
该分析基于EXPAND随机对照III期试验(NCT00678535),纳入630例有治疗前25-羟维生素D血浆水平的晚期胃食管癌患者,接受卡培他滨联合顺铂化疗或联合西妥昔单抗治疗。多数患者存在严重维生素D缺乏,但25-羟维生素D水平与生存无预后关联,也未提示其干扰西妥昔单抗疗效。作者认为需前瞻性研究探讨一线化疗期间补充维生素D的潜在获益。
要点
- 多数晚期胃癌患者存在严重维生素D缺乏。
- 治疗前25-羟维生素D水平未显示预后影响。
- 未提示25-羟维生素D水平干扰西妥昔单抗疗效。
核心结论
- 多数晚期胃癌患者存在维生素D缺乏,但无证据表明其对生存有负面影响或降低治疗反应。
- 作者认为需前瞻性研究探讨该患者队列一线化疗期间补充维生素D的潜在获益。
研究设计与样本
- 基于EXPAND随机对照III期试验(NCT00678535)的分析。
- 纳入630例有治疗前25-羟维生素D血浆水平、接受卡培他滨联合顺铂化疗或联合西妥昔单抗治疗的晚期胃食管癌患者。
- 采用Cox比例风险回归模型分析两个治疗组中低25-羟维生素D与生存的关联。
主要发现
- 多数研究患者存在严重维生素D缺乏。
- 在本患者队列中未发现25-羟维生素D血浆水平的预后影响。
- 未提示25-羟维生素D血浆水平与抗表皮生长因子受体单克隆抗体西妥昔单抗疗效之间存在干扰。
局限性
- 作者认为需前瞻性研究探讨该患者队列一线化疗期间补充维生素D的潜在获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The goal of our analysis was to study pretherapeutic circulating 25-OHD plasma levels in patients with previously untreated advanced gastric cancer treated in the randomised controlled phase III Erbitux (cetuximab) in combination with Xeloda (capecitabine) and cisplatin in advanced esophago-gastric cancer (EXPAND) trial (NCT00678535) and to explore whether low 25-OHD plasma levels are associated with worse prognosis and may compromise the clinical efficacy of cetuximab. METHODS: Six hundred thirty patients with available pretherapeutic 25-OHD plasma levels and treated with chemotherapy based on capecitabine and cisplatin, or chemotherapy and cetuximab, were included. The Cox proportional hazard regression model was used to analyse the association between low 25-OHD and survival in both treatment arms. RESULTS: Majority of study patients were found to have severe vitamin D deficiency. No prognostic impact of 25-OHD plasma levels could be found in our patient cohort, and there was no indication of an interference of 25-OHD plasma levels and the efficacy of treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab. CONCLUSIONS: Although majority of patients with advanced gastric cancer show hypovitaminosis D deficiency, there is no proof for a negative impact on survival or reduced treatment response. A prospective study is needed to investigate the potential benefit of vitamin D supplementation in this patient cohort during first-line chemotherapy.
引用
- Obermannova R, Valik D, Hasenclever D, et al. High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact. Eur J Cancer. 2019. PMID: 31195354. doi:10.1016/j.ejca.2019.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。